Guildford, UK, 27 March 2012: ReNeuron confirms that following the receipt of a notice of exercise of warrants originally issued in March 2009, it has approved the issue of 3,333,333 Ordinary Shares at the warrant exercise price of 3p per share (the “New Ordinary Shares”).
Please click on link below for webcast of Stem Cell Technical Seminar for analysts, investors and media, on 17th January 2012.
Guildford, UK, 11 January 2012: ReNeuron announces the appointment of Cenkos Securities, as Nominated Adviser and Broker to the Company, with immediate effect.
Guildford, UK, 11 January 2012: ReNeuron announces that its academic collaborators are presenting new data regarding the stability of the Company’s lead CTX stem cell line in large-scale manufacturing conditions.
Guildford, UK, 9 January 2012: ReNeuron announces that it is presenting at the Biotech Showcase 2012 conference taking place in San Francisco on 9-11 January.
ReNeuron announces that it will host a Stem Cell Technical Seminar for analysts, investors and media on 17 January 2012.
Guildford, UK, 3 January 2012: ReNeuron announces that positive data from a pivotal pre-clinical study using its lead CTX neural stem cell line in a stroke model has been published on line in the leading journal Stem Cells. An abstract can be viewed at: http://onlinelibrary.wiley.com/doi/10.1002/stem.1024/abstract.
Please click on link below for webcast of presentation by Michael Hunt, CEO at the 2011 Stem Cell on the Mesa Conference, La Jolla, CA, USA on 1st December 2011
